Bioventix Share Discussion Threads

[rcturner2] 22/8/2016 08:14

I use both advfn and investegate to find RNS data, although it seems that neither is 100% reliable.

[igbertsponk] 22/8/2016 08:07

Great update: time the price shifted up

[trident5] 22/8/2016 07:58

Can't see this RNS anywhere - but RCT's post seems excellent news.

[janeann] 22/8/2016 07:49

apad - its on advfn under news but not showing on the rival money in the morning site which is strange

[apad] 22/8/2016 07:46

Where do you look for rns announcements, RCT?
Not showing on Investegate yet.

They have outed on Seimens being their partner on cardiac troponin and commented on being pleased with progress.

Other than that nothing new I think.

apad

[rcturner2] 22/8/2016 07:45

The Board is pleased to report that revenues for the financial year ended 30
June 2016 are expected to be in excess of GBP5.3M (2015: GBP4.33M). A strong
performance during the financial year has been supplemented by a positive
exchange rate effect. Since the cost base of the Company follows the same
trajectory as in previous years, both revenues and profits before tax are
expected to be ahead of market expectations for the year ended 30 June 2016.

[rcturner2] 22/8/2016 07:08

Good trading update today, revenue and profit ahead of expectations.

[1birddog] 19/8/2016 09:26

chart look ready to roll over hairy chart

[apad] 19/8/2016 08:54

Back to 975/989.
Waste of time trying to make sense of it, just be careful.
apad

[apad] 18/8/2016 17:30

Presumably dropping the sell price so much is to discourage sellers. So, MMs have too much stock. So why not drop the buy price to encourage buyers?
Such small numbers though.....
apad

[albo76] 18/8/2016 15:33

Thanks all

[apad] 18/8/2016 11:06

Buy at 945/950 a month ago. I like that much better.
apad

[sharw] 18/8/2016 10:43

Yes, I am currently getting quotes of 942 to sell 989 to buy.

Mcap £50m and average daily trade volume (12 months) 6111 shares so not the most liquid of shares - this is one for long term holders enjoying a good yield.

[apad] 18/8/2016 09:46

That's my experience too. But you have to be careful - sale just went through at 941p.
apad

[gdjs100] 17/8/2016 20:24

The true spread is normally within the MM quotes, currently for example you can sell at 975 and buy at 989 which isn't too bad at all.

[albo76] 17/8/2016 20:10

I,m new to this stock, but like the sound of the company. can anyone tell me why the spread is so massive here Pls? Seems disproportionate. Thanks

[apad] 15/8/2016 10:26

ps
emailed Harrison on this point but it was not answered.

[apad] 15/8/2016 09:59

Post from the BVXP thread in October:
"Boros10 - 08 Oct 2015 - 13:49:56 - 168 of 301
Bioventix partner for the high sensitive Troponin analyte diagnostic partner is a top 5 player but it is not Abbott or Roche. I believe the partner is Beckman Coulter. Abbott and Roche have already launched in Europe but no one has yet secured FDA approval for the U.S. market. FinnCap's last research note said Troponin royalties could dwarf all the Company's existing royalties."

The high sensitivity troponin has a 3 hour gap between analyses. It has been approved in europe since 2011.
In the Harrison presentation he refers to 1, 2 or 3 hours.
It seems to me that the difference between 1 and 3 hours is immense.
Anyone know any more?
apad

[apad] 12/8/2016 14:21

Post 294
"I'd expected a price decline because of the imminent loss of an important income stream."

Based on this I was expecting weakness for the rest of the year.

However there has been a steady 7% (ish) rise in buying price over the last 3 weeks.
I was musing on why, given the very well-known, loss of perpetual royalty contracts, there was enough interest to allow the MMs to up the buying price.
Could be what nfs opines.

Anyway I'll hold off increasing for a while and see what happens. Probably nothing as it is August.

apad

[santar] 12/8/2016 11:50

.... or, what ragehammer just said :)

[santar] 12/8/2016 11:45

APAD,

From the interim results: ...in 18 months’ time, around 15% of the Company’s revenue will be lost due to the expiry of payments relating to one of our first license agreements.  The timing of this expiry is coincident with the expected launch of a high sensitivity troponin assay for heart attack diagnostics that uses Bioventix antibodies.  The timing of our customer’s troponin product launch is a matter under their control but our understanding is that launch is expected to take place during 2017, most likely in the EU market first. Our expectation at this time is that the dynamics of the revenue shift from these two events will not adversely affect overall sales or cash generation.  We will report again on this important issue later in the year. So the market has priced in a decline in revenue which may not happen.

Another important factor is the impact of the fall in value of sterling. From the last annual report: The majority of the Company’s revenues are denominated in either US Dollars or Euros whilst the majority of its operating costs are in Sterling. The Company is therefore exposed to foreign currency risk due to fluctuations in exchange rates. For 2015 only 5.7% of revenue was from the U.K. So with some simple maths Brexit alone will increase revenues in sterling by over 12% and OP by over 17%, more than compensating for any loss in revenue from the expiring licence agreement.

[ragehammer] 12/8/2016 11:31

BVXP are due to lose about £700k in annual revenue from mid-2017. As far as I understand it, they are hoping that the start of high-sensitivity Troponin income will make up this shortfall, although the timing is uncertain. I believe the medium/long term potential of Troponin is significantly greater than the lost revenue stream.

Another factor worth bearing in mind is that only about 5% of revenue is received in GBP. Most comes in EUR/USD. So FX alone could substantially make up for the lost revenue in GBP terms.

[hydrus] 12/8/2016 10:53

The price has already declined in any case over last few months. As that is a 'known' I would anticipate it's baked in.